← Leaderboards
Adam Mitchell Spivak
University Of Utah
$2,025,516
Attributed
$3,612,352
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $909K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,612,352 · 5
By mechanism
R56$1,683,571 · 2
R01$1,471,281 · 1
R03$228,750 · 1
R34$228,750 · 1
Top collaborators
- Joseph Christopher Mudd3 shared
- Joshua Tisdell Schiffer3 shared
Others in their field
Other Emerging Leaders on “Hiv-1”
- Yunda Huang · Fred Hutchinson Cancer Center$53,891,173
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$46,167,724
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Wilton B Williams · Duke University$19,801,567
- Priyamvada Acharya · Duke University$16,177,967
Research focus
Hiv-1Cd4 Positive T LymphocytesFda ApprovedCellsAntiretroviral TherapyInfectionPharmaceutical PreparationsImmune SystemVirusViralLymphocyteIn VivoImmunosuppressionAutologousHiv InfectionsDoseProvirusesSafetyAntiproliferative AgentsLibrariesAntigensIn Vitro TestingImmune ActivationImmune
Grant awards (7)
Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence$846,498
R01 · FY2025 · AI
Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence$624,783
R01 · FY2024 · AI
Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence$908,973
R56 · FY2023 · AI
Discovering New HIV-1 Latency Reversal Agents from Euphorbia Species$774,598
R56 · FY2022 · AI · contact PI
Tyrosine kinase inhibition to block HIV-1 persistence: a pilot study$228,750
R34 · FY2020 · AI · contact PI
Modulating Immune Senescence of Effector Lymphocytes in Chronic HIV Infection$114,375
R03 · FY2020 · AG · contact PI
Modulating Immune Senescence of Effector Lymphocytes in Chronic HIV Infection$114,375
R03 · FY2019 · AG · contact PI